Andreas Lundqvist

About me
Publications
CV
Public outreach and news

About me

Professor, Karolinska Institutet, Department of Oncology-Pathology, 2023

Associate Professor, Karolinska Institutet, 2012
Assistant Professor, Karolinska Institutet, 2009
Staff Scientist, National Institutes of Health, 2008
Research fellow, National Institutes of Health, 2005
Postdoctoral fellow, National Institutes of Health, 2003
PhD, Karolinska Institutet, 2003

Research

Our research focus on studies to understand how NK and T cells are regulated in patients with cancer. With this knowledge we aim to develop improved immunotherapies in patients with cancer.

Teaching

Completed ten weeks of pedagogic training courses.
PhD course organizer: Tumor immunology and immune therapy of cancer (#3110), Karolinska Institutet.
More than 500 hours teaching undergradates (BSc), post-graduates (MSc and PhD) and medical professionals (MD).

Articles

Article: ONCOIMMUNOLOGY. 2025;14(1):2481109
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients
Tong L; Kremer V; Neo SY; Seitz C; Tobin NP; Seliger B; Harmenberg U; Colon E; Plogell A-HS; Liu LL; Lundqvist A
Journal article: ADVANCED SCIENCE. 2025;:e13084
Targeting Cystine Metabolism in the Lung Cancer Environment Enhances the Efficacy of Immune Checkpoint Inhibition
Xu Y; Li S; Wu J; Xu S; Shen M; Wang C; Andreas L; Yu J; Xu Z; Shi Y; Liu N; Yang Y; Zhao J; Yang Y; Wang P; Yi P; Cheng J; Sun J; Li M; Xiao P; Wang K
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025;74(9):278
VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function
Tong L; Tay AHM; Cui W; Liu Y; Su Y; Lyu J; Hoedemakers L; Yang Y; Ehnman M; Seliger B; Nordlund P; Haglund de Flon F; Neo SY; Lundqvist A
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2025;117(5):qiaf011
CD73 promotes the maturation of murine NK cells and their survival in the tumor microenvironment
Parra-Tello B; Garcia-Gomez M; Rekus-Polanska E; Malgue F; Charlin S; Hernandez-Oliveras A; Reyes-Alvarez J; Rosemblatt M; Lundqvist A; Lladser A; Bono MR; Sauma D
Article: ONCOIMMUNOLOGY. 2024;13(1):2372875
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
Hamida O; Karlsson F; Lundqvist A; Gerling M; Liu LL
Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2024;43(1):107
A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Gondor A; Ostling P; Holmgren L
Article: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2024;43(1):13
Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease
Neo SY; Oliveira MMS; Tong L; Chen Y; Chen Z; Cismas S; Burduli N; Malmerfelt A; Teo JKH; Lam K-P; Alici E; Girnita L; Wagner AK; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2023;12(1):2175517
CD25^bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression
Chen Z; Tong L; Neo SY; Li S; Gao J; Schlisio S; Lundqvist A
Article: CELLS. 2023;12(17):2158
Deciphering the Role of p60AmotL2 in Epithelial Extrusion and Cell Detachment
Cui W; Subramani A; Fonseca P; Zhang Y; Tong L; Zhang Y; Egevad L; Lundqvist A; Holmgren L
Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: CANCER IMMUNOLOGY RESEARCH. 2023;11(2):217-227
Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Min ATH; Lovrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1264012
Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma
Tay AHM; Cinotti R; Sze NSK; Lundqvist A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(10):e005308
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
Neo SY; Jing X; Tong L; Tong D; Gao J; Chen Z; De Los Santos MC; Burduli N; Ferreira SDS; Wagner AK; Alici E; Rolny C; Cao Y; Lundqvist A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arner ESJ; Kiessling R; Wickstrom SL
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(5):e004592
A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
Tay AHM; Prieto-Diaz R; Neo S; Tong L; Chen X; Carannante V; Onfelt B; Hartman J; Haglund F; Majellaro M; Azuaje J; Garcia-Mera X; Brea JM; Loza MI; Jespers W; Gutierrez-de-Teran H; Sotelo E; Lundqvist A
Article: NATURE CANCER. 2022;3(2):251-261
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Article: ADVANCED SCIENCE. 2021;8(21):e2101029
Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism
Wu J; Chen Z; Wickstrom SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2021;70(11):3155-3166
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Witt K; Evans-Axelsson S; Lundqvist A; Johansson M; Bjartell A; Hellsten R
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:682627
B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion
Luu K; Schwarz H; Lundqvist A
Article: CANCERS. 2021;13(5):1175
CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma
Su Y; Tsagkozis P; Papakonstantinou A; Tobin NP; Gultekin O; Malmerfelt A; Ingelshed K; Neo SY; Lundquist J; Chaabane W; Nisancioglu MH; Leiss LW; Ostman A; Bergh J; Sedimbi S; Lehti K; Lundqvist A; Stragliotto CL; Haglund F; Ehnman M
Article: EMBO REPORTS. 2021;22(3):e51329
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25⁺/CD54⁺ NK cells
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: CELLS. 2021;10(2):353
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
Luu K; Patwardhan MV; Zeng Q; Wickstrom SL; Lundqvist A; Schwarz H
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(10):5508-5522
Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(37):22910-22919
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
He X; Yin X; Wu J; Wickstrom SL; Duo Y; Du Q; Qin S; Yao S; Jing X; Hosaka K; Wu J; Jensen LD; Lundqvist A; Salter AI; Brautigam L; Tao W; Chen Y; Kiessling R; Cao Y
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
Article: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2020;1231:45-51
The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment
Neo SY; Lundqvist A
Article: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2020;1296:319-348
Sarcoma Tumor Microenvironment
Tsagozis P; Gonzalez-Molina J; Georgoudaki A-M; Lehti K; Carlson J; Lundqvist A; Haglund F; Ehnman M
Article: SCIENTIFIC REPORTS. 2019;9(1):12150
Exhaustion of CD4+T-cells mediated by the Kynurenine Pathway in Melanoma
Pour SR; Morikawa H; Kiani N; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegner J
Article: METHODS IN MOLECULAR BIOLOGY. 2019;2032:105-114
Strategies and Techniques for NK Cell Phenotyping.
Ziqing C; Lundqvist A; Witt K
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:197-206
Evaluation of Breast Cancer and Melanoma Metastasis in Syngeneic Mouse Models.
Witt K; Lundqvist A
Article: CANCER IMMUNOLOGY RESEARCH. 2018;6(11):1417-1425
Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Article: LAB ON A CHIP. 2018;18(16):2466-2476
Acoustic formation of multicellular tumor spheroids enabling on-chip functional and structural imaging
Olofsson K; Carannante V; Ohlin M; Frisk T; Kushiro K; Takai M; Lundqvist A; Onfelt B; Wiklund M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(10):1333-1344
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lovgren T; Sarhan D; Truxova I; Choudhary B; Maas R; Melief J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017;5(1):73
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Kremer V; Ligtenberg M; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colon E; Scherman-Plogell A-H; Lundqvist A
Article: ONCOIMMUNOLOGY. 2017;6(8):e1338238
Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
Sarhan D; Leijonhufvud C; Murray S; Witt K; Seitz C; Wallerius M; Xie H; Ullen A; Harmenberg U; Lidbrink E; Rolny C; Andersson J; Lundqvist A
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: BLOOD. 2016;128(11):1475-1489
IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Article: ONCOIMMUNOLOGY. 2016;5(5):e1128613
Cripto-1 vaccination elicits protective immunity against metastatic melanoma
Ligtenberg MA; Witt K; Galvez-Cancino F; Sette A; Lundqvist A; Lladser A; Kiessling R
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2016;12(3):607-611
Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience
Murray S; Lundqvist A
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2015;64(2):225-235
CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo
Wennerberg E; Kremer V; Childs R; Lundqvist A
Article: PLOS ONE. 2015;10(10):e0139809
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
Article: CLINICAL CANCER RESEARCH. 2014;20(22):5733-5744
Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Hoog A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
Article: CLINICAL CANCER RESEARCH. 2014;20(15):4096-4106
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Article: IMMUNOBIOLOGY. 2014;219(3):189-197
Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients
Gonzalez FE; Ramirez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Saazar-Onfray F
Article: JOURNAL OF IMMUNOLOGY. 2014;192(3):1313-1319
Gap Junction Intercellular Communications Regulate NK Cell Activation and Modulate NK Cytotoxic Capacity
Tittarelli A; Mendoza-Naranjo A; Farias M; Guerrero I; Ihara F; Wennerberg E; Riquelme S; Gleisner A; Kalergis A; Lundqvist A; Lopez MN; Chambers BJ; Salazar-Onfray F
Article: JOURNAL OF IMMUNOLOGY. 2013;191(12):6241-6249
Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF
Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JPJ; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;133(7):1643-1652
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(8):1359-1368
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2013;43(1):249-257
Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Article: JOURNAL OF IMMUNOLOGY. 2012;188(5):2136-2145
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
Article: CYTOTHERAPY. 2011;13(3):269-278
Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways
Gotherstrom C; Lundqvist A; Duprez IR; Childs R; Berg L; le Blanc K
Article: JOURNAL OF CANCER. 2011;2:383-385
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
Lundqvist A; Berg M; Smith A; Childs RW
Article: STEM CELLS. 2010;28(9):1465-1475
Major Histocompatibility Complex-I Expression on Embryonic Stem Cell-Derived Vascular Progenitor Cells Is Critical for Syngeneic Transplant Survival
Ma M; Ding S; Lundqvist A; San H; Fang F; Konoplyannikov M; Berry C; Beltran LE; Chen G; Kovacic JC; Boehm M
Article: JOURNAL OF IMMUNOLOGY. 2010;184(3):1139-1142
Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells
Lundqvist A; Su S; Rao S; Childs R
Article: BLOOD. 2009;113(24):6120-6127
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
Article: BLOOD. 2009;113(4):875-882
Primitive quiescent CD34⁺ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Yong ASM; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Article: CYTOTHERAPY. 2009;11(3):341-355
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Berg M; Lundqvist A; McCoy PJ; Samsel L; Fan Y; Tawab A; Childs R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2008;118(3):1099-1109
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
Takahashi Y; Harashima N; Kajigaya S; Yokoyama H; Cherkasova E; McCoy JP; Hanada K-I; Mena O; Kurlander R; Abdul T; Srinivasan R; Lundqvist A; Malinzak E; Geller N; Lerman MI; Childs RW
Article: CYTOTHERAPY. 2008;10(8):775-783
Natural killer cell immunotherapy for cancer: a new hope
Srivastava S; Lundqvist A; Childs RW
Article: BLOOD. 2007;109(8):3603-3606
Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors
Lundqvist A; McCoy JP; Samsel L; Childs R
Article: CANCER RESEARCH. 2006;66(14):7317-7325
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(6):796-801
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
Srinivasan R; Daniels J; Fusaro V; Lundqvist A; Killian JK; Geho D; Quezado M; Kleiner D; Rucker S; Espinac V; Whiteley G; Liotta L; Petricoin E; Pittaluga S; Hitt B; Barrett AJ; Rosenblatt K; Childs RW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;133(3):305-314
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;131(1):74-79
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
Srinivasan R; Balow JE; Sabnis S; Lundqvist A; Igarashi T; Takahashi Y; Austin H; Tisdale J; Barrett J; Geller N; Childs R
Article: LANCET ONCOLOGY. 2005;6(10):809-812
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib
Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
Article: IMMUNOLOGY LETTERS. 2005;100(2):113-119
Effects of human plasma proteins on maturation of monocyte-derived dendritic cells
Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartunková J; Masucci G; Pisa P
Article: JOURNAL OF IMMUNOTHERAPY. 2005;28(3):229-235
Mature dendritic cells induce tumor-specific type 1 regulatory T cells
Lundqvist A; Palmborg A; Pavlenko M; Levitskaya D; Pisa P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;128(5):668-675
Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation
Griffith LM; McCoy JP; Bolan CD; Stroncek DF; Pickett AC; Linton GF; Lundqvist A; Srinivasan R; Leitman SF; Childs RW
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: MEDICAL ONCOLOGY. 2004;21(2):155-165
Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses
Lundqvist A; Palmborg A; Bidla G; Whelan M; Pandha W; Pisa P
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52
Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: JOURNAL OF IMMUNOTHERAPY. 2002;25(6):445-454
Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection
Lundqvist A; Noffz G; Pavlenko M; Sæboe-Larssen S; Fong T; Maitland N; Pisa P
Article: HUMAN GENE THERAPY. 2002;13(13):1541-1549
Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis
Lundqvist A; Choudhury A; Nagata T; Andersson T; Quinn G; Fong T; Maitland N; Pettersson S; Paulie S; Pisa P
Article: BRITISH JOURNAL OF CANCER. 2002;87(4):414-422
Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker
Salazar-Onfray F; López M; Lundqvist A; Aguirre A; Escobar A; Serrano A; Korenblit C; Petersson M; Chhajlani V; Larsson O; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(3):139-144
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X_L
Lundqvist A; Nagata T; Kiessling R; Pisa P
Show more

Employments

Professor, Department of Oncology-Pathology, Karolinska Institutet, 2023-

Degrees and Education

Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2003

About me

Research

Teaching

Articles

Employments

Degrees and Education

News from KI

Events from KI